CWP
PTCT icon

Concord Wealth Partners’s PTC Therapeutics PTCT Stock Holding History

Concord Wealth Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18
Closed -$1K – 1053
2020
Q4 		$1K Buy
+18
New +$1.06K ﹤0.01% 649

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Concord Wealth Partners's PTCT Position: Q1 2021 in Review

Concord Wealth Partners sold out of PTC Therapeutics (PTCT) in Q1 2021, closing a stake of 18 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in PTCT in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 207 funds tracked by Wall St. Rank hold PTCT as of Q1 2021.

  • Concord Wealth Partners reported no remaining PTC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Concord Wealth Partners sold 18 PTC Therapeutics shares in Q1 2021, an estimated $1K.
  • Concord Wealth Partners first reported a position in PTC Therapeutics in Q4 2020 and held it in 1 quarter.
  • Concord Wealth Partners's PTC Therapeutics position peaked at $1K in Q4 2020.
  • 207 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2021.

Based on Concord Wealth Partners's 13F filing for Q1 2021, filed 13 May 2021.